{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-267279","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.205589+00:00","generated_at":"2026-06-09T04:08:39.828033+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Plus Therapeutics board authorizes $500K share repurchase program","bullets":["Board approved repurchase of up to $500,000 of common stock over 12 months.","Repurchases may be made on open market or privately, subject to lender consent.","Company not obligated to buy any shares; program can be discontinued at any time."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-267279","json":"https://secwatch.observer/filing/0001193125-23-267279.json","markdown":"https://secwatch.observer/filing/0001193125-23-267279.md","text":"https://secwatch.observer/filing/0001193125-23-267279.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312523267279/0001193125-23-267279-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312523267279/d572000d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T04:08:39.828033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}